Trial Profile

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Fianlimab (Primary) ; Platinum complexes
Indications Head and neck cancer; Liver cancer; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

10 Apr 2025 Planned End Date changed from 30 Mar 2030 to 14 May 2030.
10 Apr 2025 Status changed from recruiting to active, no longer recruiting.
29 Oct 2024 Planned End Date changed from 26 Feb 2031 to 30 Mar 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com